Walgreens Reinvents Nation’s Largest Health and Wellbeing-centered Loyalty Program with myWalgreens to Offer Customers Many More Benefits
Walgreens today announced the launch of myWalgreens, a complete reinvention of its customer loyalty program to offer customers extensive new benefits, including the fastest same-day retail pickup offering available today*. Customers can now shop online and on a fully-redesigned mobile app for health and wellness items, and then pick them up in the store, curbside or at the drive-thru in as little as 30 minutes.**
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201119005676/en/
Walgreens pickup at curbside (Photo: Business Wire)
Walgreens has the nation’s largest health and wellbeing-centered customer loyalty program, with more than 100 million members. It’s now easier than ever for its members to stay well, shop conveniently and save money and time seamlessly across more than 9,000 stores, Walgreens.com and the mobile app.
The new benefits are in addition to many others already offered by Walgreens. These include an at-home delivery service through DoorDash and Postmates and a Prescription Savings Club with up to 80 percent off cash retail prices.
myWalgreens members can sign up quickly and easily for no cost, and will now receive:
- One percent Walgreens Cash rewards storewide
- Five percent Walgreens Cash rewards on Walgreens branded products
- “Only for you” exclusive deals
Additionally, the mobile app now features a broad range of health and wellness services for customers and patients, including a 24/7 pharmacy chat, access to find and book medical care and vaccination appointments, personalized health and wellness advice, real-time flu alerts and more. The previous version of the app is already very popular, and has been downloaded more than 65 million times.
“As America’s community pharmacy, Walgreens is delivering an unparalleled experience to help customers and patients manage their health and wellbeing during the most severe health crisis of our lifetimes,” said John Standley, Walgreens president. “As always, our more than 25,000 community pharmacists remain at the core of our offering. Our pharmacists and patient care teams do far more than just filling prescriptions – they provide trusted advice, personalized support and a vast range of services.”
The debut of myWalgreens marks another milestone in the company’s digital transformation. Walgreens delivers customers more and more benefits and a highly-personalized experience by working with the very best technology and customer-insight partners, including Microsoft, Adobe and Epsilon.
Online or on the app, myWalgreens members can:
Save Time and Increase Convenience
- Shop a full assortment of more than 27,000 items, including everyday health and wellness and over-the-counter essentials, as well as photos
- Add a payment method to their digital wallet for faster contactless checkout
- Redeem Walgreens Cash rewards instantly at checkout
- Choose digital receipts for quick contactless checkout and to track purchases
Stay Healthy
- Earn bonus Walgreens Cash rewards for achieving health goals
- Receive daily, personalized recommendations for health and wellness, as well as real-time local environment and health forecasts
Help Communities
- Donate their Walgreens Cash rewards to charity (the eligible charity organizations will rotate, beginning with the Full Plate Project, a program of Comic Relief U.S.’ Red Nose Day which works to end child poverty)
Starting today, current Walgreens Balance Rewards members can transfer their membership to myWalgreens at mywalgreens.com. Current Balance Rewards members have until January 31, 2021 to sign up for myWalgreens to ensure that existing rewards roll over to the new program. Over the next several months, myWalgreens will announce even more benefits for customers and patients.
Click here for myWalgreens press kit, including a logo, images and app screenshots.
About Walgreens
Walgreens (www.walgreens.com) is included in the Retail Pharmacy USA Division of Walgreens Boots Alliance, Inc. (Nasdaq: WBA), a global leader in retail and wholesale pharmacy. As America’s most loved pharmacy, health and beauty company, Walgreens purpose is to champion the health and wellbeing of every community in America. Operating more than 9,000 retail locations across America, Puerto Rico and the U.S. Virgin Islands, Walgreens is proud to be a neighborhood health destination serving approximately 8 million customers each day. Walgreens pharmacists play a critical role in the U.S. healthcare system by providing a wide range of pharmacy and healthcare services. To best meet the needs of customers and patients, Walgreens offers a true omnichannel experience, with platforms bringing together physical and digital, supported by the latest technology to deliver high-quality products and services in local communities nationwide.
* As compared to national omni-channel food and pharmacy mass retailers that offer store pick-up free-of-charge.
** For Walgreens store locations that are not open 24 hours, orders must be placed at least one hour prior to store closing in order to be eligible. Otherwise, order will be ready the following business day. Customer will be notified via email when order is ready for pickup and will be provided instructions for a drive-up experience that complies with social distancing guidelines. Orders are not guaranteed to be ready within the 30-minute time window and may be subject to change or substitution depending on product availability at the time order is placed. Orders with age-restricted items may only be picked up in store. Prescription orders not eligible but may be ordered through Walgreens Express®. To find the location and hours of a Walgreens store near you, visit Walgreens.com/FindAStore.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201119005676/en/
Contact information
Walgreens PR Contact:
Emily Hartwig-Mekstan
emily.hartwig@walgreens.com
Walgreens Boots Alliance PR Contact:
Morry Smulevitz
morry.smulevitz@walgreens.com
Investor Relations:
+1-847-315-2922
http://news.walgreens.com
@WalgreensNews
facebook.com/Walgreens
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 13:31:00 EET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 01:49:00 EET | Press release
Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive Officer, Lattice Semiconductor. The annual GSA Awards celebrate the accomplishments of the semiconductor indu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom